Live Breaking News & Updates on Ct05043090

Stay updated with breaking news from Ct05043090 . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

SAMETA Trial Evaluates Efficacy of Savolitinib Plus Durvalumab in MET-Driven Papillary RCC

The safety and efficacy achieved with the combination of savolitinib and durvalumab vs standard-of-care sunitinib or durvalumab monotherapy will be evaluated in patients with MET-driven papillary renal cell carcinoma in the phase 3 SAMETA trial. ....

United States , Dana Farber Cancer Institute , Bristol Myers Squibb , Roche Genentech , Calithera Biosciences , Tonik Choueiri , Platformq Health , Pharma Group , Corvus Pharmaceuticals , Life Sciences , Kidney Cancer Association , Alexion Pharmaceuticals , Analysis Group , Database Consortium , Gilead Sciences , Navinata Health , Sanofi Aventis , Health Interactions , Fishawack Group Of Companies , Infinity Pharmaceuticals , Kidney Cancer Research Summit , Foundation Medicine , International Metastatic , Precede Bio , Tempest Therapeutics , Arcus Biosciences ,